The FDA has extended the review period for Bluebird bio Inc's (NASDAQ: BLUE) biologics licensing applications (BLA) for its lentiviral vector gene therapies.

• The agency has pushed the applications for betibeglogene autotemcel (beti-cel) for β-thalassemia and elivaldogene autotemcel (eli-cel) for cerebral adrenoleukodystrophy (CALD).

• The revised PDUFA goal dates for beti-cel and eli-cel are August 19, 2022, and September 16, 2022.

• Related: Bluebird bio's Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical Hold.

• The FDA extended the PDUFA goal dates for beti-cel and eli-cel to allow time to review additional clinical information previously submitted by the Company in response to FDA information requests.

• The extension of the FDA review timeline does not relate to new safety events for either beti-cel or eli-cel.

• The FDA accepted bluebird's BLA submission for beti-cel for β-thalassemia for priority review in November 2021.

• Bluebird also said that it received written questions from the FDA on partial clinical hold for the lovotibeglogene autotemcel (lovo-cel) gene therapy program for sickle cell disease patients under 18 years.

• The Company continues to evaluate the impact of the partial clinical hold on its projected Q1 2023 timing for submitting the BLA.

• Price Action: BLUE shares are down 2.63% at $8.50 during the premarket session on the last check Tuesday.

See more from Benzinga

• Bluebird bio Lays Out Planned Updates Ahead Of J.P. Morgan Healthcare Conference

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.